Atara stock rises ~27% on Q2 beat, US regulatory path for tab-cel; to cut 20% staff

Aug. 09, 2022 12:41 PM ETAtara Biotherapeutics, Inc. (ATRA)By: Ravikash, SA News Editor

Rolled newspaper with the headline Quarterly Results


Atara Biotherapeutics (NASDAQ:ATRA) stock rose ~27% on Aug. 9 after the company's Q2 results beat analysts' estimates and the CEO said that the FDA recommended a possible path towards a regulatory filing for tabelecleucel (tab-cel) without the need for a new clinical study.

The company has been exploring tab-cel to treat Epstein-Barr virus positive post-transplant lymphoproliferative disease (( EBV+ PTLD)), a rare complication that can happen after a transplant.

The drug is under review in the EU and the company noted in its Aug. 8 earnings release that it expects the European Commission's (EC) approval in Q4 2022.

"We are excited about the transformative potential of ATA188 in MS and are pleased that as a result of our significant and constructive engagement, the FDA has recommended a possible path towards a tab-cel BLA filing without the need for a new clinical study,” said Atara President and CEO Pascal Touchon.

In addition, Atara said it will reduce its staff by ~20% across the organization and noted that future annual cash burn is expected to be reduced by over 20%, extending cash runway into Q1 2024.

As of June 30, cash, cash equivalents and short-term investments were $331.3M.

Atara reported net income of $18.5M in Q2, which included a $50.2M gain on the sale of the ATOM facility, compared to a net loss of -$83.8M in Q2 2021.

License and collaboration revenue grew to $51.58M, compared to $3.87M in Q2 2021.

The company said Q2 revenue mainly consisted of deferred revenue recognized due to termination of a collaboration with Bayer, and expects that license and collaboration revenues will decrease substantially in future quarters due to the termination of the Bayer agreements.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.